One Capital Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,508 shares of the company’s stock after selling 639 shares during the quarter. One Capital Management LLC’s holdings in Johnson & Johnson were worth $7,862,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter worth $4,609,399,000. Morgan Stanley increased its stake in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Nordwand Advisors LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $785,273,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.67 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were given a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 99.58%.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several recent research reports. UBS Group began coverage on Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Raymond James lowered their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $171.57.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Game-Changing News For AMD And Its Shareholders
- How to Read Stock Charts for Beginners
- Can Chegg’s AI Pivot Save It From Disruption?
- Best Investment Strategy in 2023: Determine the Right One for You
- Enovix: A Rising Power in the Lithium-Ion Industry
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
